CDMO supply chains are quickly becoming value chains, where each stage from drug discovery to distribution presents an opportunity to enhance the final product's value for patients. This shift is underscored by increased collaborations between CDMOs and CROs, as highlighted in the 2023 trend report titled "The Nexus Between Patient and Big Pharma," developed by Thermo Fisher Scientific and CPHI.
Our webinar explores insights from the report, focusing specifically on the synergies between CDMOs and CROs. These synergies hold the potential to streamline drug development processes and expedite the delivery of safe, effective, and high-quality treatments to patients. Learn from industry experts as they explore how these collaborations can drive innovation and efficiency in the pharmaceutical industry.
Key takeaways include: